FY2025 Earnings Forecast for HURA Issued By Zacks Small Cap

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Investment analysts at Zacks Small Cap raised their FY2025 earnings estimates for shares of TuHURA Biosciences in a research report issued on Monday, November 17th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings per share of ($0.66) for the year, up from their previous estimate of ($0.68).

Several other equities analysts also recently commented on HURA. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Wednesday, October 8th. Wall Street Zen upgraded TuHURA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Finally, Maxim Group lowered their target price on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $10.33.

TuHURA Biosciences Trading Down 9.3%

HURA opened at $1.75 on Thursday. TuHURA Biosciences has a 1-year low of $1.74 and a 1-year high of $7.20. The stock’s fifty day simple moving average is $2.41 and its 200 day simple moving average is $2.69. The stock has a market cap of $89.70 million and a PE ratio of -1.01.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HURA. Suncoast Equity Management lifted its position in TuHURA Biosciences by 4.4% during the second quarter. Suncoast Equity Management now owns 104,409 shares of the company’s stock worth $233,000 after purchasing an additional 4,412 shares during the period. Virtu Financial LLC acquired a new position in shares of TuHURA Biosciences in the 3rd quarter valued at approximately $26,000. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth approximately $27,000. Intech Investment Management LLC bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth approximately $29,000. Finally, Invesco Ltd. acquired a new stake in shares of TuHURA Biosciences during the 2nd quarter worth approximately $30,000. Institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.